Ephedra bronchodilator use likely to escape FDA prohibition -- NNFA counsel Young.

EPHEDRA USE IN BRONCHODILATORS LIKELY WILL BE PERMITTED TO CONTINUE if FDA proceeds with regulatory action limiting use of the herb in dietary supplement products, Anthony Young, of the Washington, D.C. law firm Piper & Marbury, predicted in an Oct. 20 presentation at the Natural Products Expo East in Baltimore, Md. Young, who is general counsel to the National Nutritional Foods Association, participated in an Oct. 11 meeting on ephedra between FDA and a number of dietary supplement groups. The agency hopes to issue a proposal on ephedra by the end of the year.